摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(5-Nitropyridin-2-yl)malonic acid | 131189-22-5

中文名称
——
中文别名
——
英文名称
2-(5-Nitropyridin-2-yl)malonic acid
英文别名
2-(5-nitropyridin-2-yl)propanedioic acid
2-(5-Nitropyridin-2-yl)malonic acid化学式
CAS
131189-22-5
化学式
C8H6N2O6
mdl
——
分子量
226.14
InChiKey
JMVXWBWVEMRTFQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    480.3±45.0 °C(Predicted)
  • 密度:
    1.689±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.1
  • 重原子数:
    16
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    133
  • 氢给体数:
    2
  • 氢受体数:
    7

文献信息

  • HETEROCYCLIC COMPOUND
    申请人:Takeda Pharmaceutical Company Limited
    公开号:EP2832734A1
    公开(公告)日:2015-02-04
    The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
    本发明提供了一种用于预防或治疗自身免疫性疾病(例如牛皮癣、类风湿关节炎、炎症性肠病、干燥综合征、贝赫切特病、多发性硬化症、系统性红斑狼疮等)等的药剂,其具有优越的Tyk2抑制作用。 本发明涉及一种由下式表示的化合物 其中每个符号如规范中定义的那样,或其盐。
  • [EN] INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL<br/>[FR] INHIBITEURS DU CANAL À POTASSIUM DE LA MEDULLA EXTERNE DU REIN
    申请人:MERCK SHARP & DOHME
    公开号:WO2013090271A1
    公开(公告)日:2013-06-20
    The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds act as diuretics and natriuretics and are valuable pharmaceutically active compounds for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension and conditions resulting from excessive salt and water retention.
    本发明提供了式(I)的化合物及其药用可接受的盐,这些化合物是ROMK(Kir1.1)通道的抑制剂。这些化合物作为利尿剂和利尿剂,并且是治疗和预防包括高血压在内的心血管疾病以及由过多盐分和潴留导致的疾病的有价值的药用活性化合物。
  • Indazole Derivatives
    申请人:Ishibashi Asako
    公开号:US20080269211A1
    公开(公告)日:2008-10-30
    This invention relates to compounds of the formula (I): or pharmaceutically acceptable salts thereof, wherein: R 1 , R 2 , R 3 , A and m are each as described herein and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT 4 agonistic activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders, cardiac failure, heart arrhythmia, diabetes and apnea syndrome.
    本发明涉及式(I)的化合物或其药学上可接受的盐,其中:R1、R2、R3、A和m如本文所述,并且包含这种化合物的组合物以及使用这种化合物治疗由5-HT4激动活性介导的疾病,例如但不限于胃食管反流病、胃肠疾病、胃动力障碍、非溃疡性消化不良、功能性消化不良、肠易激综合征(IBS)、便秘、消化不良、食管炎、胃食管疾病、恶心、中枢神经系统疾病、阿尔茨海默病、认知障碍、呕吐、偏头痛、神经系统疾病、疼痛、心血管疾病、心力衰竭、心律失常、糖尿病和呼吸暂停综合征。
  • Process for Preparation of Nonnatural Amino Acid and Intermediate Thereof
    申请人:Ishii Yutaka
    公开号:US20070208180A1
    公开(公告)日:2007-09-06
    A process for the preparation of a nonnatural amino acid represented by the following formula (C): which is characterized by reacting a compound represented by the following formula (A1), a compound represented by the following formula (A2) and a compound represented by the following formula (A3) (step 1): to form a compound represented by the following formula (B): and then subjecting the compound (B) to deprotection of protective groups of carboxyl groups and to decarboxylation (wherein X 1 and X 2 are a leaving group, R 1 is an aromatic group, an unsaturated heterocyclic group, or R 6 CO group, R 2 and R 3 are a protected carboxyl group, R 4 is a protected amino group, R 5 is hydrogen atom, an aliphatic hydrocarbon group, an aromatic group, or a heterocyclic group, R 6 is an aromatic group or an unsaturated heterocyclic group, etc., and p, q and r are an integer of 0 to 10).
    一种制备以下式(C)所表示的非天然氨基酸的方法,其特征在于将以下式(A1)、以下式(A2)和以下式(A3)所表示的化合物进行反应(步骤1):以形成以下式(B)所表示的化合物,然后将化合物(B)进行羧基保护基的去保护和脱羧作用(其中X1和X2是离去基,R1是芳香基、不饱和杂环基或R6CO基,R2和R3是保护羧基,R4是保护基,R5是氢原子、脂肪烃基、芳香基或杂环基,R6是芳香基或不饱和杂环基等,p、q和r是0到10的整数)。
  • N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS
    申请人:Bagley Scott William
    公开号:US20120225900A1
    公开(公告)日:2012-09-06
    The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of said compound, wherein R 1 , R 2 , R 3 and R 4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    本发明提供了式(I)的化合物或其药学上可接受的盐,其中R1、R2、R3和R4如本文所述;其药物组合物;以及在治疗动物中通过抑制乙酰辅酶A羧化酶酶的作用调节的疾病、症状或疾患中使用该化合物的方法。
查看更多